News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aureus Pharma Changes its Name to Aureus Sciences and Launches a New, Comprehensive Life Science Application Web Portal



1/20/2011 9:50:58 AM

Paris, France, January 20, 2011 - Aureus Pharma, a leading provider of knowledge management solutions to accelerate research and development in the life sciences industry, announces today a change of name to Aureus Sciences, and the launch of a new, comprehensive application web portal to bring easier, faster and better access to its wide-range of advanced drug discovery tools and knowledge.

Aureus Sciences has built its new web portal around its unique knowledge platform, the culmination of ten years’ intensive development. This analyzes, indexes and organizes critical chemical and bioactivity information of the druggable genome into best-in-class scientific databases for use by researchers involved in the drug discovery process.

The portal is designed to provide easier access and live experience for Aureus Sciences’ highly sophisticated tools with several search and visualization options. It is unique in offering access to editorial content, the application server and community networks. The tools include applications and content, as well as help for users to understand the value of proposed solutions better and faster in a unique way. Medicinal chemists, pharmacologists, drug metabolism and pharmacokinetics scientists can navigate in the portal and conduct searches in Aureus’ knowledge bases that contain more than three million biological activities. Scientists can also filter results, such as compound activity, therapeutic target affinity, ADME (Absorption, Distribution, Metabolism and Excretion) and DDI (Drug Drug Interaction) properties. A unique feature of the portal is the display of results in a scientifically relevant context through a selection of “dashboards” that show detailed coverage of the topics in Aureus Sciences’ knowledge space.

Further drill-down searches are also available free of charge to registered users for a limited period of time. Full access is available under a named user license agreement.

“The new Aureus-Sciences application portal is a major achievement for our company,” said Dr Jason Theodosiou, president & CEO of Aureus Sciences. “For the first time we are offering a unique single-point access to all of our tools, applications, notes, scientific communications and technical documentation. This will make it substantially easier for our prospective customers to make use of our know-how, provide more comprehensive interaction and help them accelerate their research projects with data they can trust.”

In parallel with the launch of the new portal, the company will continue its operations under the new name, Aureus Sciences, as the company believes that it more accurately reflects its activities.

The new webportal is available at http://www.aureus-sciences.com.

About Aureus Sciences

Aureus Sciences provides a range of scientific knowledge solutions enabling biopharmaceutical companies to better understand the relationships of biological targets to compounds under evaluation. Aureus Sciences’ experts continuously monitor and organize the most relevant information from the scientific literature, including experimental in vitro and in vivo protocols. This detailed knowledge forms the AurSCOPE(R) database line, focusing on the human body’s main therapeutic targets: GPCRs, kinases, ion channels, proteases and nuclear receptors. Additional AurSCOPE(R) databases relate to safety, toxicology, and pharmacokinetics (ADME, hERG). Consolidating all the therapeutic targets, the AurSCOPE(R) Global Pharmacology Space (GPS) provides researchers with the most comprehensive available coverage of the “druggable” genome. Applications include AurQUEST(R), the web-based query tool, DDI Predict(R) for drug-drug interactions, and AurPROFILER(R), the compound profiling visualization tool. Headquartered in Paris, France, Aureus Sciences’ information solutions are proven to streamline the discovery process for many of the world’s most successful biopharmaceutical companies and prestigious research institutions.

Lynne Chapman ANDREW LLOYD & ASSOCIATES http://www.ala.com lynne@ala.com

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND Tel: +44 1273 675100 Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES